SCHEMBL29967557

SCHEMBL29967557

O=C(Nc1cc(F)cc(C(F)(F)F)c1)c1ccc2c(c1)N(Cc1ccc3[nH]cnc3c1)CC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.44
▸ HDAC6 Q9UBN7 2/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ POLB P06746 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ DDR2 Q16832 6/20 0.40
▸ DDR1 Q08345 5/20 0.40
▸ ABL1 P00519 2/20 0.40
▸ BCR P11274 2/20 0.40
▸ KIT P10721 1/20 0.40
▸ NTRK1 P04629 1/20 0.39
▸ NTRK3 Q16288 1/20 0.39
▸ NTRK2 Q16620 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ CPT2 P23786 1/20 0.38
▸ CPT1A P50416 1/20 0.38
▸ CPT1B Q92523 1/20 0.38
▸ TNF P01375 1/20 0.37
▸ PTGER4 P35408 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27083027 1.00 MAPT (0.44) MAPTHDAC6HDAC8POLBHTT
SCHEMBL29967680 0.90 MAPT (0.45) MAPTHDAC6HDAC8POLBSMN1; SMN2
SCHEMBL27081782 0.90 MAPT (0.45) MAPTHDAC6HDAC8POLBSMN1; SMN2
SCHEMBL27081785 0.86 NR2E1 (0.53) DDR2DDR1ABL1BCRKIT
SCHEMBL29967592 0.86 NR2E1 (0.53) DDR2DDR1ABL1BCRKIT
SCHEMBL29967753 0.81 PRMT5 (0.42) MAPTHDAC6HDAC8HTTABL1
SCHEMBL27083011 0.81 PRMT5 (0.42) MAPTHDAC6HDAC8HTTABL1
SCHEMBL27083036 0.80 DDR2 (0.45) HDAC6HDAC8DDR2DDR1ABL1
SCHEMBL30697224 0.77 CDK9 (0.43) HDAC6HDAC1KMT2A
SCHEMBL27081690 0.77 CDK9 (0.43) HDAC6HDAC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP claimed
EP-4313972-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP claimed
CN-117062812-A Indoline derivatives as DDR inhibitors 奇斯药制品公司 2023-11-14 — — CN claimed
WO-2022200577-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-09-29 — — WO claimed
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 MAPT 2994/4885HDAC6 1289/4885HDAC8 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback